Icotinib (BPI-2009H)

Catalog No.S2922 Batch:S292201

Print

Technical Data

Formula

 

C22H21N3O4
Molecular Weight 391.42 CAS No. 610798-31-7
Solubility (25°C)* In vitro DMSO 78 mg/mL (199.27 mM)
Ethanol 7 mg/mL (17.88 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Icotinib (BPI-2009H) is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).
Targets
EGFR [1]
5 nM
In vitro Icotinib inhibits EGFR activity in a dose-dependent manner, with an IC50 value of 5 nM and complete inhibition at 62.5 nM. Icotinib selectively solely inhibits the EGFR members including the wild type and mutants with inhibition efficacies of 61-99%. Icotinib blocks EGFR-mediated intracellular tyrosine phosphorylation in human epidermoid carcinoma A431 cells in a dose-dependent manner. Meanwhile, in our proliferation assay performed on A431, BGC-823, A549, H460, HCT8, KB and Bel-7402 cell lines, we found that the relative sensitivity of cell lines to Icotinib is A431 > BGC-823 > A549 > H460 > KB > HCT8 and Bel-7402. Icotinib exhibits a broad spectrum of antitumor activity and it is especially effective against tumors expressing higher levels of EGFR. [1]
In vivo Icotinib shows an antitumor effect in different types of xenografts. Icotinib inhibits tumor growth at a rate of 51.5%, 31.0% and 67.4% in the A431, A549 and H460 xenografts at a dose of 120 mg/kg, respectively. [1]

Protocol (from reference)

Kinase Assay:[1]
  • Biochemical kinase assays

    In the in vitro kinase assays, 2.4 ng/μL EGFR protein is mixed with 32 ng/μL Crk in 25 μL kinase reaction buffer containing 1 μM cold ATP and 1 μCi 32P-γ-ATP. The mix is incubated with Icotinib at 0, 0.5, 2.5, 12.5 or 62.5 nM on ice for 10 min followed by incubation at 30 °C for 20 min. After quenching with SDS sample buffer at 100 °C for 4 min, the protein mix is resolved by electrophoresis in a 10% SDS-PAGE gel. The dried gel is then exposed to the PhosphorImager to detect radioactivity. Quantification is performed by ImageQuant software. In this methodology the radioactive signal inversely correlates with kinase activity.
Cell Assay:[1]
  • Cell lines

    A431, BGC-823, A549, H460, HCT8, KB and Bel-7402 cells.

  • Concentrations

    ~25 μM

  • Incubation Time

    96 h

  • Method

    Cells (103 /well) are seeded into 96-well plates in RPMI-1640 medium containing 10% FBS and grown in a 5% CO2 incubator at 37 °C. After 24 h, cells are treated with Icotinib at 0, 0.78, 1.56, 3.125, 6.25, 12.5 or 25 μM for 96 h. Cell proliferation is calculated by subtracting the mean absorbance value on day 0 from the mean absorbance value on day 4.
Animal Study:[1]
  • Animal Models

    A431, A549, H460 and HCT8 xenografts Nude mice

  • Dosages

    30, 60 and 120 mg/kg/day

  • Administration

    p.o.

Customer Product Validation

, , Oncotarget, 2015, 5(12):4529-42.

Data from [Data independently produced by , , Oncogene, 2017, 36(45):6235-6243]

Selleck's Icotinib (BPI-2009H) has been cited by 8 publications

Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer [ Am J Cancer Res, 2024, 14(1):33-51] PubMed: 38323283
A community challenge for a pancancer drug mechanism of action inference from perturbational profile data [ Cell Rep Med, 2022, 3(1):100492] PubMed: 35106508
Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors [ Transl Res, 2022, S1931-5244(22)00244-4] PubMed: 36347492
Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors [ Clin Transl Oncol, 2022, 10.1007/s12094-022-02854-3] PubMed: 35666454
HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. [ Nat Cell Biol, 2019, 21(8):1027-1040] PubMed: 31332347
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer [Wang J Oncogene, 2017, 36(45):6235-6243] PubMed: 28714960
CD166-mediated epidermal growth factor receptor phosphorylation promotes the growth of oral squamous cell carcinoma [Guodong Jia, et al. Oral Oncology, 2016, 10.1016/j.oraloncology.2016.05.010]
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. [Wang DS, et al. Oncotarget, 2015, 5(12):4529-42] PubMed: 24980828

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.